Pipeline

pipeline & programs

Focused Innovation With a Clear Path to Clinic

Lahjavida Bio's development strategy centers on disciplined execution — advancing our lead Dye-Drug Conjugate (DDC) toward IND readiness while unlocking the broader potential of our modular platform.

Contact Us

Lahjavida Bio is committed to advancing a first-in-class modality with the potential to transform how cancer therapies are delivered — beginning with our lead DDC and expanding thoughtfully across the solid-tumor landscape.

Lead DDC Program

Our lead DDC candidate is currently undergoing preclinical optimization, with upcoming studies focused on:

  • Tumor-selective uptake
  • Payload release
  • Safety to support IND-enabling activities

This program represents the first step in establishing a new small-molecule precision oncology modality with meaningful advantages over large-molecule ADCs.

Scalable Platform Expansion

In parallel, we are building a scalable pipeline of next-generation DDC constructs, each designed to validate:

  • Additional payload classes
  • Linker innovations
  • Tumor-targeting applications

Strategic Growth Path

As these programs mature, we will selectively pursue:

  • Partnerships to extend the platform into high-need oncology indications
  • Accelerate global development.

DDC Pipeline Overview

Conjugate Dye Linker Payload
DDC1 Dye 1 Linker #1 SN38
DDC2 Dye 2 Linker #1 SN38
DDC3 Dye 1 Linker #2 MMAE
DDC4 Dye 1 Linker #3 Doxorubicin
DDC5 Dye 2 Linker #3 Doxorubicin
DDC6 Dye 1 Linker #4 MMAE
DDC7 Dye 1 Linker #5 Doxorubicin
DDC8 Dye 1 Linker #6 Doxorubicin
DDC9 Dye 1 Linker #6 Exatecan
DDC10 Dye 1 Linker #7 Duel Payload Exatecan/MMAE

* SN38 is a *topoisomerase I inhibitor. It stabilizes the Topo I–DNA cleavage complex, leading to DNA breaks during replication and ultimately cell death.

** MMAE (monomethyl auristatin E) is a highly potent microtubule (tubulin) polymerization inhibitor that induces G2/M cell-cycle arrest and apoptosis by disrupting the mitotic spindle.

*** Doxorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, causing DNA breaks, and also generates free radicals that contribute to cytotoxicity.